June 20, 2018June 20, 2018
Potential Alzheimer’s Treatment Targeting Bacteria Seen as Safe in Early Trial, Cortexyme Says
News
COR388, Cortexyme‘s investigational compound to treat Alzheimer’s, was safe and well-tolerated in healthy volunteers taking part in a Phase 1 ... Read more
June 18, 2018June 18, 2018
Memory Training Tool Using Virtual Reality Available for Alzheimer’s Patients
News
Sokhey announced it recently launched Swann VR, the world’s first virtual reality memory training device specifically designed for people with ... Read more
June 15, 2018June 15, 2018
Phase 3 Trials of Lanabecestat in Alzheimer’s Patients Stopped for Lack of Efficacy, Eli Lilly and AstraZeneca Announce
News
Eli Lilly and AstraZeneca announced that they are stopping two global Phase 3 trials of lanabecestat, an amyloid beta-targeting treatment ... Read more
June 13, 2018June 13, 2018
Red Sox Support Cure Alzheimer’s Fund, Disease Research at June Game Against Detroit Tigers
News
The Boston Red Sox hosted Cure Alzheimer’s Fund at a recent baseball game against the Detroit Tigers to raise ... Read more
June 8, 2018
Alzheimer’s Therapy Elenbecestat Reduces Brain Amyloid Levels, is Safe and Well-Tolerated, Trial Shows
News
Treatment with the investigational compound elenbecestat reduced brain amyloid beta levels and was safe and well-tolerated, according to Phase 2 clinical ... Read more
June 8, 2018June 11, 2018
Responding to Common Myths About Alzheimer’s Disease
News
June is World Alzheimer’s and Brain Awareness Month, and James E. Galvin, MD, MPH, a leading neuroscientist and associate ... Read more
June 6, 2018June 6, 2018
Type 2 Diabetes Therapies May Help Relieve Alzheimer’s Symptoms, Researchers Say
News
Medications for type 2 diabetes may help treat symptoms of Alzheimer’s, as these two conditions share common disease mechanisms, ... Read more
June 4, 2018June 4, 2018
Cognition Therapeutics Awarded $6.6M to Support 2 Elayta Trials for Alzheimer’s
News
Cognition Therapeutics has received two multi-year grants from the National Institute on Aging (NIA) totaling $6.6 million to fund ... Read more
June 1, 2018June 1, 2018
Phase 1 Trial Assessing Stem Cell Therapy Recruiting Alzheimer’s Patients in Florida
News
A Phase 1 trial to evaluate the safety and effectiveness of Longeveron’s allogeneic mesenchymal stem cells (LMSCs) in patients ... Read more
May 30, 2018May 30, 2018
UsAgainstAlzheimer’s Launches AD PACE, New Patient-Caregiver Initiative
News
UsAgainstAlzheimer’s recently launched the Alzheimer’s Disease Patient and Caregiver Engagement (AD PACE) initiative as a groundbreaking partnership between the ... Read more
May 25, 2018May 25, 2018
Study Investigates ‘Friendsourcing’ as a Way to Provide Support to Alzheimer’s Caregivers
News
A new Facebook app can provide emotional support to unpaid caregivers of Alzheimer’s disease patients, according to a study. Researchers ... Read more
May 23, 2018May 23, 2018
Janssen Halts Clinical Development of Alzheimer’s Candidate Atabecestat Due to Liver Issues
News
Janssen pulled the plug on a Phase 2b/3 trial and a Phase 2 safety study of its Alzheimer’s disease experimental ... Read more

June 20, 2018June 20, 2018

Potential Alzheimer’s Treatment Targeting Bacteria Seen as Safe in Early Trial, Cortexyme Says

News

COR388, Cortexyme‘s investigational compound to treat Alzheimer’s, was safe and well-tolerated in healthy volunteers taking part in a Phase 1 clinical trial, the company announced. COR388 is a first-in-class bacterial ... Read more

June 18, 2018June 18, 2018

Memory Training Tool Using Virtual Reality Available for Alzheimer’s Patients

News

Sokhey announced it recently launched Swann VR, the world’s first virtual reality memory training device specifically designed for people with Alzheimer’s disease. The company, and product, were created by Taegh ... Read more

June 15, 2018June 15, 2018

Phase 3 Trials of Lanabecestat in Alzheimer’s Patients Stopped for Lack of Efficacy, Eli Lilly and AstraZeneca Announce

News

Eli Lilly and AstraZeneca announced that they are stopping two global Phase 3 trials of lanabecestat, an amyloid beta-targeting treatment candidate for Alzheimer’s, because of an apparent lack of benefit. ... Read more

June 13, 2018June 13, 2018

Red Sox Support Cure Alzheimer’s Fund, Disease Research at June Game Against Detroit Tigers

News

The Boston Red Sox hosted Cure Alzheimer’s Fund at a recent baseball game against the Detroit Tigers to raise awareness about Alzheimer’s and bring attention to the nonprofit group’s ... Read more

June 8, 2018

Alzheimer’s Therapy Elenbecestat Reduces Brain Amyloid Levels, is Safe and Well-Tolerated, Trial Shows

News

Treatment with the investigational compound elenbecestat reduced brain amyloid beta levels and was safe and well-tolerated, according to Phase 2 clinical trial results. The presence of amyloid beta plaques is a ... Read more

June 8, 2018June 11, 2018

Responding to Common Myths About Alzheimer’s Disease

News

June is World Alzheimer’s and Brain Awareness Month, and James E. Galvin, MD, MPH, a leading neuroscientist and associate dean at Florida Atlantic University’s Charles E. Schmidt College of ... Read more

June 6, 2018June 6, 2018

Type 2 Diabetes Therapies May Help Relieve Alzheimer’s Symptoms, Researchers Say

News

Medications for type 2 diabetes may help treat symptoms of Alzheimer’s, as these two conditions share common disease mechanisms, according to recent research. Fernanda De Felice, PhD, an associate ... Read more

June 4, 2018June 4, 2018

Cognition Therapeutics Awarded $6.6M to Support 2 Elayta Trials for Alzheimer’s

News

Cognition Therapeutics has received two multi-year grants from the National Institute on Aging (NIA) totaling $6.6 million to fund two clinical studies of Elayta (CT1812), Cognition’s lead candidate for ... Read more

June 1, 2018June 1, 2018

Phase 1 Trial Assessing Stem Cell Therapy Recruiting Alzheimer’s Patients in Florida

News

A Phase 1 trial to evaluate the safety and effectiveness of Longeveron’s allogeneic mesenchymal stem cells (LMSCs) in patients with Alzheimer’s disease is currently looking for participants, the biopharmaceutical ... Read more

May 30, 2018May 30, 2018

UsAgainstAlzheimer’s Launches AD PACE, New Patient-Caregiver Initiative

News

UsAgainstAlzheimer’s recently launched the Alzheimer’s Disease Patient and Caregiver Engagement (AD PACE) initiative as a groundbreaking partnership between the public and private sectors to identify and prioritize the needs ... Read more